Patents Assigned to Nagasaki University
  • Publication number: 20220011297
    Abstract: A method may predict risk of onset of severe interstitial pneumonia caused by an immune checkpoint inhibitor to achieve a safe and highly effective cancer immunotherapy. Any one or more selected from: (a) cell count or proportion of V?2+?? T cells in peripheral blood mononuclear cells isolated from a subject; (b) cell count or proportion of V?2+?? T cells after antigenic stimulation in peripheral blood mononuclear cells isolated from a subject; (c) cell count or proportion of V?2+?? T cells in peripheral blood T cells isolated from a subject; and (d) cell count or proportion of V?2+?? T cells after antigenic stimulation in peripheral blood T cells isolated from a subject are measured, and the risk of onset of severe interstitial pneumonia is predicted by using the cell count or proportion as an index.
    Type: Application
    Filed: October 1, 2019
    Publication date: January 13, 2022
    Applicants: NAGASAKI UNIVERSITY, Foundation for Biomedical Research and Innovation at Kobe
    Inventors: Yoshimasa TANAKA, Hiroaki SENJU, Hiroshi MUKAE, Masanori FUKUSHIMA
  • Publication number: 20210307890
    Abstract: A device for efficiently attaching a sheet-shaped object to a target site includes a support body for supporting a sheet-shaped object, and a protective member having a low coefficient of friction for protecting one surface of the support, in which the support body supporting the sheet-shaped object is rolled while being protected by the protective member and can be inserted into a tubular body.
    Type: Application
    Filed: June 18, 2021
    Publication date: October 7, 2021
    Applicants: NAGASAKI UNIVERSITY, TERUMO KABUSHIKI KAISHA
    Inventors: Yusuke SAKAI, Susumu EGUCHI, Yasuhiro MARUYA, Fumiya OHASHI, Tadashi SAMESHIMA
  • Patent number: 10913949
    Abstract: The present invention provides a therapeutic agent for a muscle weakness symptom (sarcopenia) or a metabolic disease, containing a ?-crystallin (CRYM) inhibitory substance as an active ingredient. The inhibitory substance is selected from the group consisting of an antisense nucleic acid against CRYM, an RNAi-inducing nucleic acid against CRYM and a ribozyme against CRYM, expression vectors of these, an antagonist antibody against CRYM, and a low molecular weight compound that inhibits activity of CRYM.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: February 9, 2021
    Assignee: NAGASAKI UNIVERSITY
    Inventor: Yusuke Ono
  • Publication number: 20200390937
    Abstract: Disclosed are embodiments of a sheet-shaped cell culture for promoting healing of a lumen organ having a damaged part, particularly tissue of a duodenum, a method for producing a sheet-shaped cell culture. Also disclosed are embodiments of a method for regenerating a damaged part in a lumen organ using a sheet-shaped cell culture described herein.
    Type: Application
    Filed: August 31, 2020
    Publication date: December 17, 2020
    Applicants: NAGASAKI UNIVERSITY, TERUMO KABUSHIKI KAISHA
    Inventors: Yasuhiro MARUYA, Ryo MATSUMOTO, Shinichiro KOBAYASHI, Kengo KANETAKA, Susumu EGUCHI, Ken OHNITA, Keiichi HASHIGUCHI, Fumiya OHASHI, Masaki MATSUMURA
  • Publication number: 20200367737
    Abstract: A cover (220, 320, 420) for covering a part in a circumferential direction of an outer circumferential surface of a rigid endoscope 10 includes an outer cover portion (222, 322, 422) having flexibility and an inner cover portion (223, 323, 423) provided on an inner surface of the outer cover portion (222, 322, 422) and configured to define a flow passage for a washing fluid to be supplied to an observation window portion 14 of the rigid endoscope 10, and the outer cover portion(222, 322, 422) is mounted onto the outer circumferential surface of the rigid endoscope 10 by the outer cover portion (222, 322, 422) bending.
    Type: Application
    Filed: August 2, 2017
    Publication date: November 26, 2020
    Applicants: Nagasaki University, TryTec Co., Ltd.
    Inventors: Keitaro MATSUMOTO, Takeshi NAGAYASU, Katsunori TAKAGI, Hiroshi TAKEZAKI, Junji MORI
  • Patent number: 10734726
    Abstract: A planar antenna includes a patch conductor formed on a front surface of a dielectric substrate 20 so to be obliquely arranged in relation to an orthogonal axis of the dielectric substrate, the patch conductor having an elliptic shape; a microstrip line 40 for feeding power to a bottom part of the patch conductor; and a ground conductor plate 50 formed on a back surface of the dielectric substrate at a position thereof that is not overlapped with the patch conductor. By forming the patch conductor to be inclined only by ?, circular polarization characteristics in which axial ratio is 3 dB or less are given and the wideband such that the frequency bandwidth in which VSWR characteristics are 2 or less is 2 through 5 GHz and the wideband in UWB High band can be attained. The antenna characteristics in which any radiation directivity on the zenith direction does not depend on the frequency are obtained.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: August 4, 2020
    Assignee: Nagasaki University
    Inventor: Takafumi Fujimoto
  • Publication number: 20200063143
    Abstract: The problem to be solved by the present invention is to provide a method of producing isoprenoids including ascofuranone, ilicicolin A, and ascochlorin and derivatives thereof in a high yield as compared to the conventional art, which method enables industrial-scale production of isoprenoids. The problem can be solved by a method of producing isoprenoids such as ascofuranone, ilicicolin A, and ascochlorin, including using a transformant obtained by transformation with biosynthetic genes for ascofuranone, ilicicolin A, or ascochlorin or a knockout organism for these genes to obtain isoprenoids such as ascofuranone, ilicicolin A, and ascochlorin.
    Type: Application
    Filed: May 11, 2018
    Publication date: February 27, 2020
    Applicants: KIKKOMAN CORPORATION, NAGASAKI UNIVERSITY
    Inventors: Yasuko ARAKI, Yasutomo SHINOHARA, Kiyoshi KITA
  • Patent number: 10563249
    Abstract: According to one embodiment, there is provided a nucleic acid primer set that amplifies a ZEBOV gene. An F1 sequence includes at least 13 consecutive bases included in SEQ ID NO: 31 or 64. An F2 sequence includes at least 13 bases included in SEQ ID NO: 62 or 63. An F3 sequence includes at least 13 bases included in SEQ ID NO: 29, 36, 38, 55, 56, 57, 58, 59, 60, 61 or 61. A B1c sequence includes at least 13 bases included in SEQ ID NO: 68, 69, 70, 71, 72, 73, 74 or 75. A B2c sequence includes at least 13 bases included in SEQ ID NO: 65 or 66. A B3c sequence includes at least 13 bases included in SEQ ID NO: 34, 67, 82 or 83.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: February 18, 2020
    Assignees: Nagasaki University, Canon Madical Systems Corporation
    Inventors: Jiro Yasuda, Yohei Kurosaki
  • Patent number: 10532065
    Abstract: The novel bisphosphonic acid ester derivatives represented by the following formula (1): Y—Cy—(NH)m—(CH2)n—C(X)(PO(OR1)(OR2))2??(1) wherein each symbol is as defined in the DESCRIPTION, which has an amino group substituted by a heterocyclic group or a heterocyclic group containing a nitrogen atom, and the acid moiety is esterified with a POM group, an n-butanoyloxymethyl (BuOM) group and the like, exhibit a superior direct or indirect cytotoxicity effect on tumor cells and virus infected cells.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: January 14, 2020
    Assignee: NAGASAKI UNIVERSITY
    Inventors: Yoshimasa Tanaka, Kenji Matsumoto, Kosuke Hayashi, Yuki Sakai, Nagahiro Minato
  • Patent number: 10280188
    Abstract: A series of fluorine-containing bisphosphonic acids in which an alkylamine side chain is added, a series of fluorine-containing bisphosphonic acids in which an amino group substituted by a heterocyclic group or a heterocyclic group containing a nitrogen atom is added, to the carbon atom of P—C(F)—P, and a series of fluorine-containing bisphosphonate derivatives in which the acid moiety thereof is esterified by an alkoxymethyl group such as POM group, n-butanoyloxymethyl (BuOM) group and the like, that is, the fluorine-containing bisphosphonic acid and fluorine-containing bisphosphonate derivative represented by the following formula (I): wherein each symbol is as defined in the DESCRIPTION, can efficiently induce proliferation of peripheral blood ?? T cells that express V?2V?2 T cell receptor having superior cytotoxicity against tumor cells and virus infected cells, immunize tumor cells and virus infected cells, and can induce cytotoxicity by ?? T cells.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: May 7, 2019
    Assignee: Nagasaki University
    Inventors: Yoshimasa Tanaka, Satoshi Mizuta, Hiroshi Ueda
  • Patent number: 10183007
    Abstract: The present invention relates to a composition containing as its main component proanthocyanidin oligomer to which a substance having a phloroglucinol ring structure or resorcinol ring structure has been bonded and reduced in the molecular weight, which is obtained by heating plant materials containing proanthocyanidin polymer or extract thereof with a substance having a phloroglucinol ring structure or resorcinol ring structure in an acidic aqueous solution, production method thereof, and uses of the composition in health products and pharmaceutical products. According to the invention, proanthocyanidin oligomer having physiological activity, to which a substance having a phloroglucinol ring structure or resorcinol ring structure has been bonded and reduced in the molecular weight to such a level that the oligomer can be absorbed into living body, which has been conventionally difficult to obtain at high yield from plant raw materials, can be produced efficiently and easily.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: January 22, 2019
    Assignees: Usien Pharmaceutical Co., Ltd., Amino Up Chemical Co., Ltd., Nagasaki University
    Inventors: Takashi Tanaka, Gen-ichiro Nonaka, Isao Kohno, Hajime Fujii, Takashi Nakagawa, Hiroshi Nishioka
  • Patent number: 10175229
    Abstract: The present invention aims to provide a novel compound for measuring cellular cytotoxicity or cell proliferation capacity accurately with high reproducibility, conveniently and rapidly, and a measurement method of cellular cytotoxicity or cell proliferation capacity by using the compound. The present invention relates to a compound represented by the formula (I): wherein R1 is a substituent, R2 and R3 are each an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group, Y is a substituent, n is an integer of 0-3, Z is a single bond, —O—, —S—, —SO—, —SO2—, or —NR4— (R4 is a hydrogen atom or a substituent), and A is an optionally substituted C1-6 alkylene group) or a salt thereof.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: January 8, 2019
    Assignee: NAGASAKI UNIVERSITY
    Inventors: Yoshimasa Tanaka, Yuki Sakai, Satoshi Mizuta, Hiroshi Ueda
  • Patent number: 10130357
    Abstract: To reduce the risk of damaging organs in a body while delivering a thread during surgery, an instrument for delivering a surgical thread has a grip, an outer cylinder fixed the grip, a hollow needle extending inside the outer cylinder and being configured to be moved relative to the outer cylinder in an axial direction and a loop configured to be housed in the outer cylinder. An end of the outer cylinder is bent in a state where force is not applied. The hollow needle is exposed from the outer cylinder when puncturing skin or etc., and the hollow needle is housed in the outer cylinder when it travels near organs which should not be damaged.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: November 20, 2018
    Assignee: Nagasaki University
    Inventors: Susumu Eguchi, Tamotu Kuroki, Taiichiro Kosaka, Takakazu Ishimatu, Syunji Moromugi
  • Publication number: 20180282733
    Abstract: The present invention provides a therapeutic agent for a muscle weakness symptom (sarcopenia) or a metabolic disease, containing a ?-crystallin (CRYM) inhibitory substance as an active ingredient. The inhibitory substance is selected from the group consisting of an antisense nucleic acid against CRYM, an RNAi-inducing nucleic acid against CRYM and a ribozyme against CRYM, expression vectors of these, an antagonist antibody against CRYM, and a low molecular weight compound that inhibits activity of CRYM.
    Type: Application
    Filed: September 9, 2016
    Publication date: October 4, 2018
    Applicant: NAGASAKI UNIVERSITY
    Inventor: Yusuke ONO
  • Patent number: 9980937
    Abstract: The present invention aims to provide a pharmaceutical agent for the prophylaxis and/or treatment of Alzheimer's disease, which has a novel action mechanism and shows less side effects. A polyphenol derivative having liposolubility enhanced by the introduction of at least one kind of a liposoluble group selected from the group consisting of a chain saturated hydrocarbon group, a chain unsaturated hydrocarbon group, a cyclic saturated hydrocarbon group, a cyclic unsaturated hydrocarbon group, an aromatic hydrocarbon group, a liposoluble vitamin residue and a sterol residue has an action to potentiate neprilysin activity, and is useful as a pharmaceutical agent for the prophylaxis and/or treatment of Alzheimer's disease.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: May 29, 2018
    Assignee: NAGASAKI UNIVERSITY
    Inventors: Nobuhisa Iwata, Keiro Shirotani, Masashi Asai, Takashi Tanaka
  • Patent number: 9976968
    Abstract: There is provided a crack detection system in which a crack can be detected from a strain distribution of a part to be detected of an object. After taking the image of the part to be detected of the detection object by the imaging unit, the heat is applied by the heating unit. Furthermore, image of the part to be detected are taken again and an image analysis unit analyzes the images before and after applying the heat to acquire a strain distribution of the part to be detected, so that the crack can be detected based on difference in a state of strain between a place where the crack exist and the other place. Therefore, taking the images of the part to be detected including its coating layer enables the analysis to progress without removing the coating layer to detect the crack.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: May 22, 2018
    Assignees: SAGA UNIVERSITY, NAGASAKI UNIVERSITY
    Inventors: Yukihiro Ito, Kazuhisa Shiki, Hiroshi Matsuda, Akira Demizu
  • Patent number: 9939404
    Abstract: A CO sensor includes a solid electrolyte substrate, a sensing electrode, and a reference electrode, and outputs electromotive forces in accordance with CO concentrations. The sensing electrode and the reference electrode are provided on the same surface of the solid electrolyte substrate. The sensing electrode contains a metal oxide such as Bi2O3 that generates a positive electromotive force response when coming into contact with CO. The reference electrode contains a metal oxide such as CeO2 that generates a negative electromotive force response when coming into contact with CO.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: April 10, 2018
    Assignees: Figaro Engineering Inc., Nagasaki University
    Inventors: Yasuhiro Shimizu, Takeo Hyodo, Taro Ueda, Hirotaka Takeda, Kai Kamada
  • Publication number: 20180054001
    Abstract: A planar antenna includes a patch conductor formed on a front surface of a dielectric substrate 20 so to be obliquely arranged in relation to an orthogonal axis of the dielectric substrate, the patch conductor having an elliptic shape; a microstrip line 40 for feeding power to a bottom part of the patch conductor; and a ground conductor plate 50 formed on a back surface of the dielectric substrate at a position thereof that is not overlapped with the patch conductor. By forming the patch conductor to be inclined only by ?, circular polarization characteristics in which axial ratio is 3 dB or less are given and the wideband such that the frequency bandwidth in which VSWR characteristics are 2 or less is 2 through 5 GHz and the wideband in UWB High band can be attained. The antenna characteristics in which any radiation directivity on the zenith direction does not depend on the frequency are obtained.
    Type: Application
    Filed: December 11, 2015
    Publication date: February 22, 2018
    Applicants: Nagasaki University, GIT Japan Incorporated
    Inventor: Takafumi FUJIMOTO
  • Publication number: 20180022769
    Abstract: A series of fluorine-containing bisphosphonic acids in which an alkylamine side chain is added, a series of fluorine-containing bisphosphonic acids in which an amino group substituted by a heterocyclic group or a heterocyclic group containing a nitrogen atom is added, to the carbon atom of P—C(F)—P, and a series of fluorine-containing bisphosphonate derivatives in which the acid moiety thereof is esterified by an alkoxymethyl group such as POM group, n-butanoyloxymethyl (BuOM) group and the like, that is, the fluorine-containing bisphosphonic acid and fluorine-containing bisphosphonate derivative represented by the following formula (I): wherein each symbol is as defined in the DESCRIPTION, can efficiently induce proliferation of peripheral blood ?? T cells that express V?2V?2 T cell receptor having superior cytotoxicity against tumor cells and virus infected cells, immunize tumor cells and virus infected cells, and can induce cytotoxicity by ?? T cells.
    Type: Application
    Filed: February 1, 2016
    Publication date: January 25, 2018
    Applicant: Nagasaki University
    Inventors: Yoshimasa TANAKA, Satoshi MIZUTA, Hiroshi UEDA
  • Publication number: 20170369940
    Abstract: According to one embodiment, there is provided a nucleic acid primer set that amplifies a ZEBOV gene. An F1 sequence includes at least 13 consecutive bases included in SEQ ID NO: 31 or 64. An F2 sequence includes at least 13 bases included in SEQ ID NO: 62 or 63. An F3 sequence includes at least 13 bases included in SEQ ID NO: 29, 36, 38, 55, 56, 57, 58, 59, 60, 61 or 61. A B1c sequence includes at least 13 bases included in SEQ ID NO: 68, 69, 70, 71, 72, 73, 74 or 75. A B2c sequence includes at least 13 bases included in SEQ ID NO: 65 or 66. A B3c sequence includes at least 13 bases included in SEQ ID NO: 34, 67, 82 or 83.
    Type: Application
    Filed: June 19, 2017
    Publication date: December 28, 2017
    Applicants: Nagasaki University, Toshiba Medical Systems Corporation
    Inventors: Jiro YASUDA, Yohei Kurosaki